Why is Glenmark Pharma falling/rising?

As of 09-Jul, Glenmark Pharmaceuticals Ltd. is currently priced at Rs 1,820.85, reflecting a decrease of Rs 3.45 or 0.19%. The stock has been underperforming recently, having fallen for the last two days with a total decline of 2.23%. Despite this short-term drop, Glenmark has shown strong performance over the past week, with a 3.09% increase, and has outperformed the benchmark Sensex over the last month and year, with returns of 13.74% and 34.08%, respectively. The stock is also trading above its moving averages, indicating a generally positive trend, and has seen a significant increase in delivery volume, suggesting rising investor participation. The company’s strong financials, including a low Debt to EBITDA ratio and consistent profit growth, support its valuation, although it has recently underperformed its sector by 0.39%.
In the broader market context, Glenmark's recent performance contrasts with the Sensex, which has only increased by 0.15% over the past week. The stock's ability to generate consistent returns over the last three years, along with high institutional holdings, suggests that it has strong backing from knowledgeable investors. However, the recent decline may be attributed to short-term market fluctuations rather than fundamental weaknesses, as the company has reported positive results for the last four quarters and continues to trade at a discount compared to its peers. Overall, while the stock is experiencing a temporary setback, its long-term outlook remains positive based on its financial health and market position.